tings, and an examination of how physiochemical characteristics and particle sizes are associated with risk of disease. Chapter 3 provides an overview of the epidemiologic and clinical literature on beryllium sensitization and CBD. Chapter 4 presents information mainly from animal studies on the pathogenesis and mode of action of CBD and information on genetic susceptibility. Chapter 5 focuses on the evidence of beryllium’s carcinogenic potential and considers carcinogenic risk estimates. Other health end points, such as reproductive and developmental effects, are reviewed in Chapter 6. Finally, Chapter 7 discusses the design of a beryllium exposure- and disease-management program for workers in the Air Force.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement